Blog
RSS FeedPosted by Michael Wonder on 08 Mar 2019
High price of cystic fibrosis drug not political, firm's boss tells MPs
8 March 2019 - CEO of company that makes Orkambi denies being ‘political minion’ for Donald Trump. ...
Posted by Michael Wonder on 06 Mar 2019
In UK and Ireland, SMA patients demand reimbursement for Spinraza
6 March 2019 - A drug appraisal committee of Britain’s NICE met in Manchester, England, for the third and final ...
Posted by Michael Wonder on 06 Mar 2019
Firm in NHS row over cystic fibrosis drug paid almost no UK tax
6 March 2019 - European division of Vertex made loss while paying large sum to profitable US owner. ...
Posted by Michael Wonder on 06 Mar 2019
NICE evidence request for Blincyto for acute lymphoblastic leukaemia
6 March 2019 - NICE has requested further evidence on Amgen’s Blincyto (blinatumomab) for the treatment of adults with acute ...
Posted by Michael Wonder on 05 Mar 2019
NHS England’s medicines chief: stop ‘salami slicing’ and get faster market access
1 March 2019 - Pressure will be maintained on costs, despite VPAS price cap deal. ...
Posted by Michael Wonder on 05 Mar 2019
How to fix a problem like Orkambi? Solutions suggested ahead of showdown
5 March 2019 - Approaches used in France and Germany could help break deadlock. ...
Posted by Michael Wonder on 05 Mar 2019
Future unrelated medical costs need to be considered in cost effectiveness analysis
5 March 2019 - New medical technologies that prolong life result in additional health care use in life years gained. Some ...
Posted by Michael Wonder on 04 Mar 2019
Vertex chief Jeffrey Leiden to weigh in on Orkambi inquiry
4 March 2019 - Vertex’s long-running spat with NHS England has amounted to a legal inquiry scheduled to begin this Thursday, ...
Posted by Michael Wonder on 27 Feb 2019
Pharma industry swamped with no-deal Brexit info, says BIA
27 February 2019 - Deluge comes just as prime minister hints at delay. ...
Posted by Michael Wonder on 27 Feb 2019
Economic analysis falls short when it comes to medicines’ value
26 February 2019 - For the past two decades, a plethora of organisations identified by various innocuous acronyms (e.g., NICE) ...
Posted by Michael Wonder on 26 Feb 2019
They can’t get their medicines. So they’re moving to Scotland.
26 February 2019 - Families in England are preparing to leave the country in a desperate bid to obtain a cystic ...
Posted by Michael Wonder on 26 Feb 2019
How will Brexit affect health services in the UK? An updated evaluation
25 February 2019 - All forms of Brexit are bad for health, but some are worse than others. ...
Posted by Michael Wonder on 25 Feb 2019
Family fight for cancer treatment in USA because drugs not available in UK
25 February 2019 - A mother of four from Downham Market in west Norfolk says she won't live to 50 ...
Posted by Michael Wonder on 25 Feb 2019
Prescriptions to rise to £9 from April
25 February 2019 - The government has announced another rise in prescription costs for medicines dispensed on the NHS in ...
Posted by Michael Wonder on 23 Feb 2019
Timely, consistent, transparent assessment of market access evidence: implementing tools based on the HTA Core Model in a pharmaceutical company
21 February 2019 - Evidence requirements and assessment methods access differ between health technology assessment agencies. ...